Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
Open accessThe DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. METHODS AND FINDINGS: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. The primary endpoints were cardiovascular mortality, myocardial infarction, and stroke-singly and as a composite endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as a composite endpoint, progression of renal disease. Secondary endpoints were angina pectoris and hospitalization for heart failure. In all, 71 trials (103,120 participants), with a total of 14 different regimens, were pooled using network meta-analyses. When compared with ACE inhibitor, no other RAS blocker used in monotherapy and/or combination was associated with a significant reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval [CrI] 0.90-1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79-1.19), DR inhibitor plus ACE inhibitor (1.32; 95% CrI 0.96-1.81), and DR inhibitor plus ARB (1.00; 95% CrI 0.73-1.38). For the risk of progression of renal disease, no significant differences were detected between ACE inhibitor and each of the remaining therapies: ARB (OR 1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72-1.29), DR inhibitor plus ACE inhibitor (0.99; 95% CrI 0.65-1.57), and DR inhibitor plus ARB (1.18; 95% CrI 0.78-1.84). No significant differences were showed between ACE inhibitors and ARBs with respect to all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or doubling serum creatinine. Findings were limited by the clinical and methodological heterogeneity of the included studies. Potential inconsistency was identified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for these single endpoints. CONCLUSIONS: In adults with diabetes, comparisons of different RAS blockers showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes. Compared with monotherapies, the combination of an ACE inhibitor and an ARB failed to provide significant benefits on major outcomes. Clinicians should discuss the balance between benefits, costs, and potential harms with individual diabetes patients before starting treatment. REVIEW REGISTRATION: PROSPERO CRD42014014404.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in people with diabetes (25): ACE inhibitors (67,68), ARBs (67,68), thiazide-like diuretics (69), or dihydropyridine calcium channel blockers (70).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [67]
Experimental — accuracy not yet measuredIn the citing paper
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in people with diabetes: ACE inhibitors (60,61), ARBs (60,61), thiazide-like diuretics (62), or dihydropyridine calcium channel blockers (63).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 3×
“Our review was prospectively registered in PROSPERO and also adheres to the recently developed PRISMA reporting standards for network meta-analyses (S1 Checklist) [44].”
MethodMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Inference from iterative simulation using multiple sequences
Gelman, A., & Rubin, D. B. (1992) · Statistical Science · doi:10.1214/ss/1177011136 · Cited by 16,627 · cited 1×
“We assessed convergence on the basis of Brooks–Gelman–Rubin plots [71].”
MethodVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Cited by
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in patients with diabetes: ACE inhibitors (58,59), angiotensin receptor blockers (ARBs) (58,59), thiazide-like diuretics (60), or dihydropyridine calcium channel blockers (61).”
BackgroundDiabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
“In general, ACE inhibitors and ARBs are considered to have similar benefits and risks, and if one is not tolerated, the other can often be used (65,83).”
BackgroundTreatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 485
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in patients with diabetes: ACE inhibitors (26,27), angiotensin receptor blockers (ARBs) (26,27), thiazide-like diuretics (28), or dihydropyridine calcium channel blockers (29).”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
“During pregnancy, treatment with ACE inhibitors, angiotensin receptor blockers (ARBs), and spironolactone are contraindicated as they may cause fetal damage.”
BackgroundInfluential10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Catalá-López, F., Hutton, B., Núñez-Beltrán, A., Page, M. J., Ridao, M., Macías Saint-Gerons, D., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180355 · Cited by 396
Self-citationAngiotensin-Converting Enzyme Inhibitors in Hypertension
Messerli, F. H., Bangalore, S., Bavishi, C., & Rimoldi, S. F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.058 · Cited by 349
“Similarly, in a network meta-analysis of 71 trials with 103,120 diabetic participants, no significant differences were documented between ACE inhibitors and ARBs with respect to all-cause mortality, CV mortality, MI, stroke, angina pectoris, hospitalization for heart failure, end-stage renal disease, or doubling of se…”
Result10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Therapeutic potential of curcumin in diabetic complications
Parsamanesh, N., Moossavi, M., Bahrami, A., Butler, A. E., & Sahebkar, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.012 · Cited by 211
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
Hypertension in patients with type 2 diabetes mellitus: Targets and management
Pavlou, D. I., Paschou, S. Α., Anagnostis, P. G., Spartalis, Μ., Spartalis, E. D., Vryonidou, A., Tentolouris, N., & Siasos, G. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.013 · Cited by 126
Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice
Verma, A., Xu, K., Du, T., Zhu, P., Liang, Z., Liao, S., Zhang, J., Raizada, M. K., Grant, M. B., & Li, Q. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.007 · Cited by 99
Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?
Veroniki, A. A., Straus, S. E., Rücker, G., & Tricco, A. C. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.02.009 · Cited by 87
ACE inhibitors and ARBs: Managing potassium and renal function
Momoniat, T., Ilyas, D., & Bhandari, S. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18024 · Cited by 98
Hypertension and diabetes mellitus: highlights of a complex relationship
Yildiz, M., Esenboğa, K., & Oktay, A. A. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000748 · Cited by 94
Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
Sharma, A., Mittal, S., Aggarwal, R., & Chauhan, M. K. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00151-w · Cited by 99
Hyperfiltration-mediated Injury in the Remaining Kidney of a Transplant Donor
Srivastava, T., Hariharan, S., Alon, U. S., McCarthy, E. T., Sharma, R., El‐Meanawy, A., Savin, V. J., & Sharma, M. (2018) · Transplantation · doi:10.1097/tp.0000000000002304 · Cited by 73
Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease
Patel, D. M., Bose, M., & Cooper, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062218 · Cited by 70
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 78
“139 ARBs have similar effects in patients with diabetes 140 ; and in older people, ARBs significantly decrease stroke.”
BackgroundRenin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review
Alshahrani, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1101068 · Cited by 78
Nehme, A., & Zibara, K. (2017) · Hypertension Research · doi:10.1038/hr.2017.65 · Cited by 63
Persson, F., Lindhardt, M., Rossing, P., & Parving, H.-H. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316652047 · Cited by 54
Li, Y., Xu, H. W., Wu, W., Ye, J., Fang, D., Shi, D., & Li, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23816 · Cited by 45
“Although the functions of ACEIs and ARBs in preventing complications of NAFLD have been widely investigated in mice, clinical data from patients are lacking, [17] and the effectiveness of ARBs in treating NAFLD remains controversial.”
BackgroundPreventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 47
“Several meta-analyses (however, most of them mixing patients with type 1 and type 2 diabetes) support the use of ACE inhibitors in diabetic patients with renal diabetic nephropathy, especially in the presence of significant albuminuria [34,50,51].”
ResultBrazilian Guidelines of Hypertension – 2025
Brandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Armstrong, A. D. C., Mulinari, R. A., Feitosa, A. D. M., Gomes, M. A. M., Barbosa, E. C. D., Moura-Neto, J. A., Neves, M. F., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250624 · Cited by 156
Zhang, R., Mamza, J. B., Morris, T., Godfrey, G., Asselbergs, F. W., Denaxas, S., Hemingway, H., & Banerjee, A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02234-2 · Cited by 45
Brandt, N., Johansen, M. L., Rasmussen, J., Forman, J. L., Holm, M. R., Faber, J. O., Rossignol, P., Schou, M., & Kistorp, C. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.005 · Cited by 34
Nistor, I., SUTTER, J. D., Drechsler, C., Goldsmith, D. J. A., Soler, M. J., Tomson, C., Więcek, A., Donciu, M., Bolignano, D., Biesen, W. V., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx072 · Cited by 30
“[36] published a network meta-analysis in adults with diabetes and focused on the comparisons of different RAS blockers.”
BackgroundJiang, L., Zhu, R., Bu, Q., Li, Y., Shao, X., Gu, H., Kong, J., Luo, L., Long, H., Guo, W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0613-8 · Cited by 32
Silvariño, R., Rios, P. G., Baldovinos, G., Chichet, M. A., Perg, N., Solá, L., Saona, G., Souza, N. D., Lamadrid, V., & Gadola, L. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000500925 · Cited by 32
Wen, Z., Zhan, J., Li, H., Xu, G., Ma, S., Zhang, J., Li, Z., Ou, C., Yang, Z., Cai, Y., et al. (2021) · Theranostics · doi:10.7150/thno.53644 · Cited by 30
“Thus, pharmacological antagonism of the RAS through AT1R blockers (ARB drugs) evolves as the cornerstone of clinical therapy for human heart failure [7].”
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 24
Abdelhafiz, A. H. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00773-y · Cited by 26
The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease
Leon, S. J., & Tangri, N. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.06.029 · Cited by 25
Catalá-López, F., Hutton, B., Driver, J. A., Page, M. J., Ridao-López, M., Valderas, J. M., Alonso‐Arroyo, A., Forés-Martos, J., Martínez, S., Gènova-Maleras, R., et al. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0466-y · Cited by 24
Self-citationAntihypertensive treatment and renal protection: Is there a J‐curve relationship?
Viazzi, F. C., Leoncini, G., Grassi, G. M., & Pontremoli, R. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13396 · Cited by 20
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02763-1 · Cited by 23
“This approach was used successfully by other researchers [11, 15].”
MethodDiabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 22
Цукровий діабет і артеріальна гіпертензія
Сергієнко, В. О., & Serhiyenko, O. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.2.2021.230573 · Cited by 30
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Packer, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13191 · Cited by 17
Kurano, M., Tsukamoto, K., Sakai, E., & Yatomi, Y. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63249 · Cited by 17
Strauss, M. H., & Hall, A. S. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.09.011 · Cited by 17
Cai, J., Huang, X., Zheng, Z., Lin, Q., Peng, M., & Shen, D. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy001 · Cited by 16
Shulman, R., Yang, W., Cohen, D. L., Reese, P. P., Cohen, J. B., Cohen, D., Appel, L. J., Chen, J., Feldman, H. I., Go, A. S., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.05.008 · Cited by 16
Chang, Z., Zou, H., Xie, Z., Deng, B., Que, R., Huang, Z., Weng, G., Wu, Z., Pan, Y., Wang, Y., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14663 · Cited by 12
Hui, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_6 · Cited by 13
Leon, S. J., & Tangri, N. (2022) · Kidney360 · doi:10.34067/kid.0000952022 · Cited by 11
Chábová, V. Č., & Červenka, L. (2017) · Physiological Research · doi:10.33549/physiolres.933607 · Cited by 12
“…in many human diseases, such as hypertension, heart failure, diabetes and chronic kidney disease (Bakris 2010, Bavishi et al. 2016, Braunwald 2015, Catalá-López et al. 2016, Chaugai et al. 2016, Cice et al. 2010, Cohn et al. 2001, Osborne et al. 2017, Palmer et al. 182 Čertíková Chábová and…”
Blood Pressure Control and Cardiovascular/Renal Outcomes
Dojki, F. K., & Bakris, G. L. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.008 · Cited by 14
Fıcı, F., Arı, E., Yüce, E. İ., Kanuncu, S., Makel, W., Tarım, B. A., & Robles, N. R. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00358-1 · Cited by 13
Yi, X., Yang, S., Yang, J., Chen, X., Zhang, A., Zeng, Q., Luo, W., Li, Q., & Hu, J. (2024) · Drugs · doi:10.1007/s40265-024-02092-7 · Cited by 9
Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial
Meng, C., Song, Z., Zhang, L., Geng, Y., Sun, J., Miao, G., & Liu, P. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0583 · Cited by 7
Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis
Fan, G., Lin, L., Zuo, H., Yan, R., & Xu, C. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03799-y · Cited by 8
“…observed to decrease mortality by up to 55% among patients with PCI (OR 0.45, 95% CI (0.26, 0.77), P = 0.0039, It has been demonstrated that patients with T2DM and CVD who undergo PCI are at an increased risk of developing CIN due to the elevated levels of insulin resistance and uric acid [23, 24].”
InfluentialØstergaard, H. B., Read, S. H., Sattar, N. A., Franzén, S., Halbesma, N., Dorresteijn, J. A. N., Westerink, J., Visseren, F. L. J., Wild, S. H., Eliasson, B., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05020422 · Cited by 6
Keyvanshokooh, E., Zhalechian, M., Shi, C., Oyen, M. P. V., & Kazemian, P. (2025) · Management Science · doi:10.1287/mnsc.2019.03211 · Cited by 19
Kim, Y. H., Her, A., Jeong, M. H., Kim, B., Hong, S., Kim, S., Ahn, C., Kim, J., Ko, Y., Choi, D., et al. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107574 · Cited by 6
Basutkar, R. S., Cutinha, R. M., Sathish, V., Shahil, A., & Najad Saneen, C. K. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998301228240625065230 · Cited by 4
Asgharpour, M., Kalan, M. E., Mirhashemi, S. H., & Alirezaei, A. (2019) · Immunopathologia Persa · doi:10.15171/ipp.2019.16 · Cited by 6
“In a large meta-analysis of randomized placebocontrolled trials, on patients with hypertension and no heart failure, it was indicated that the efficiency and safety of ARBs (angiotensin-receptor blockers) and ACEIs were comparable (17).”
BackgroundInfluentialTocci, G., Citoni, B., Presta, V., Leoncini, G., Viazzi, F. C., Bonino, B., Volpe, M., & Pontremoli, R. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02257-3 · Cited by 4
What We Learned with Recent Network Meta-analyses on Atherosclerosis Prevention and Treatment
Giordano, A., Peruzzi, M., Marullo, A. G. M., Frati, G., Sciarretta, S., Napolitano, G., & Biondi‐Zoccai, G. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0645-2 · Cited by 4
Guo, J. S., Naimi, A. I., Brooks, M. M., Muldoon, M. F., Orchard, T. J., & Costacou, T. (2019) · Annals of Epidemiology · doi:10.1016/j.annepidem.2019.12.004 · Cited by 4
“, thiazides and calcium channel blockers) for decreasing cardiovascular risk (15,16).”
BackgroundСтолов, С. В. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-4-64-78 · Cited by 5
“Эффективная блокады РААС влияет на прогноз как у больных кардиоваскулярного и почечного риска, так и при сахарном диабете, аутоиммунных заболеваниях и др [14,58].”
Xu, H., Liu, J., Gu, L., Zang, X., Liu, N., Pan, Y., Jiang, C., Li, Y., Jiang, G., Mao, Z., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112413 · Cited by 3
Yang, X., Shao, L.-L., Mi, Y.-J., Zhang, W., Liu, N.-Y., Liu, R.-B., Zhou, X., Zhang, W., & Tian, Q. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107830 · Cited by 4
Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes
Sabbour, H. M., Almahmeed, W. A., Alawadi, F., Shehab, A. M., Zubaidi, A. A., Bashier, A. M., Ghulam, A. R., Rashid, F., Zaky, H., Kassem, H. H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395630 · Cited by 4
Validated registry of pre-dialysis chronic kidney disease: description of a large cohort
Huaira, R. M. N. H., de Paula, R. B., Bastos, M. G., Colugnati, F. A. B., & Fernandes, N. M. D. S. (2018) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-3841 · Cited by 3
Flash glucose monitoring in the practice of pediatric endocrinologist
Okminyan, G., Kiseleva, E., Latyshev, O. Y., Касаткина, Э. П., & Самсонова, Л. Н. (2021) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2021-10-2-130-137 · Cited by 3
Staff, T. P. M. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002064 · Cited by 3
2024 Thai guidelines on the treatment of hypertension
Kunanon, S., Kotruchin, P., Chattranukulchai, P., Chotruangnapa, C., Roubsanthisuk, W., Vathesatogkit, P., Kunavisarut, T., Silaruks, S., Tejavanija, S., Wataganara, T., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0034 · Cited by 3
Zhao, Q., Shen, J., Lu, J., Li, F., Jiang, Q., & Wang, Y. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033448 · Cited by 4
Updated management for patients with cardiovascular disease and diabetes
Dugan, J. A., Butts, A., Collins, B. S., Saini, P. S., & Bradley, S. (2019) · JAAPA · doi:10.1097/01.jaa.0000569804.46658.ce · Cited by 2
Hong, D., Shi, W., Lu, X., Lou, Y., & Li, L. (2020) · Medical Science Monitor · doi:10.12659/msm.923696 · Cited by 1
Скобелева, К. В., & Tyrtova, L. V. (2021) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2021-25-2-43-51 · Cited by 1
Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes
Leung, A. A. C. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_24 · Cited by 2
Омариевна, У. Ф., Demidova, T. Y., & Panteleeva, S. V. (2024) · FOCUS Endocrinology · doi:10.15829/2713-0177-2024-5-1-06 · Cited by 1
Kim, Y. H., Her, A., Jeong, M. H., Kim, B., Hong, S., Kim, S., Ahn, C., Kim, J., Ko, Y., Choi, D., et al. (2020) · Medicine · doi:10.1097/md.0000000000021289 · Cited by 1
“40).([11]) Anigotensin II has been shown to indirectly induce differentiation of adipocyte precursors into mature fat cell.”
BackgroundIs clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
Gong, T., & HALL, S. A. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0574-9
Protección renal con ARA II e IECA en pacientes diabéticos Normotensos-Normoalbuminuricos
Crespo, A. O. O., Cedillo, A. X. O., Cedillo, A. E. O., Cedillo, P. O. O., & López, V. S. (2018) · Revista Clínica Escuela de Medicina UCR-HSJD · doi:10.15517/rc_ucr-hsjd.v8i4.34245
HTA et diabète : quelle prise en charge en 2018 ?
Bouhanick, B. (2018) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2018.09.015
Gorb, Y. G., Strona, V. I., & Komir, I. (2019) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs04.01.008 · Cited by 2
Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery
Ansari, S., & Miras, A. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-54064-7_102-1
Столов, С. В., & Privalov, K. A. (2021) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov89729 · Cited by 1
In Type 2 Diabetes Patients Cardiovascular-Renal Disease is a Lifetime Risk Factor
Kashif, J., Ullah, A. A., & Khan, I. N. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs221631230
Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery
Ansari, S., & Miras, A. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_102
Sun, Y., Zhang, Z., Sun, W., Jin, D., An, X., Zhang, Y., Yang, C., Zhang, Y., Duan, Y., Kang, X., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4455400
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
Kosjerina, V., Scheuer, S. H., Carstensen, B., Jørgensen, M. E., Brock, B., Christensen, H. R., Andersen, G. S., & Rungby, J. (2024) · medRxiv · doi:10.1101/2024.02.23.24303300
Antiglycation Efficacy: Unknown Pleiotropicity of Known Drugs
Зайцева, Е. Н., Lebedev, P. A., Юрьевна, С. Т., Масленникова, Н. О., & Шарова, О. В. (2024) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-024-03259-y
Kamath, A., Acharya, N., Kossi, M. E., & Tavakoli, M. (2025) · Wiley eBooks · doi:10.1002/9781394205066.ch10
Risk Factors and Treatment of Cardiovascular Disease in Type 2 Diabetes
周, 欣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151242
Managing diabetes and cardiovascular disease
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.4.18
Fang, Z. A., Zhao, J., & Gong, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05094-9
“Despite existing treatments such as diuretics and renin-angiotensin system inhibitors [5], identifying modifiable risk factors for CRS remains an area of concern.”
Metadata
- Authors
- Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., Tabarés-Seisdedos, R., & Hutton, B.
- Affiliations
- Universitat de València (ES)
- IRCCS San Raffaele Roma (IT)
- The University of Texas Health Science Center at Houston (US)
- Agencia Española de Medicamentos y Productos Sanitarios (ES)
- University of Ottawa (CA)
- Corresponding author
- Catalá-López, Ferrán
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-08
- Volume
- 13
- Issue
- 3
- Pages
- e1001971
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC4783064
- OpenAlex
- W2292998606
- Cited by
- 109
- References
- 103
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 18 · 2019: 12 · 2018: 16 · 2017: 10 · 2016: 2
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-06-10)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Digital Collections of Colorado (Colorado State University) (submittedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Generalitat Valenciana (PROMETEOII/2015/021)
- Centro de Investigación Biomédica en Red de Salud Mental
- INCLIVA Instituto de Investigación Sanitaria
- Canadian Institutes of Health Research
- Instituto de Salud Carlos III (PROMETEOII/2015/021, PI14/00894, PI14/)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- renin-angiotensin system blockade, diabetes mellitus, ACE inhibitors, angiotensin receptor blockers, renin inhibitors, cardiovascular outcomes, renal outcomes, end-stage renal disease, cardiovascular mortality, myocardial infarction, stroke, heart failure hospitalization, angina pectoris, combination therapy, all-cause mortality, serum creatinine
- MeSH terms
- Renin Inhibitors, Adult, Angina Pectoris, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Heart Failure, Hospitalization, Humans, Kidney Failure, Chronic, Myocardial Infarction, Renin-Angiotensin System, Stroke, Diabetes Complications, Renal Insufficiency, Chronic, Secondary Prevention, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.